Arno Therapeutics to Present at 26th Annual ROTH Conference

FLEMINGTON, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Glenn Mattes is scheduled to present at the 26th Annual ROTH Conference, being held March 9-12, 2014 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA.

Mr. Mattes will present on Wednesday, March 12, 2014 at 8:00 a.m. PT to attending investors. During his presentation, Mr. Mattes will discuss Arno's business and growth strategy, clinical developments of its lead oncology candidate, onapristone, and accompanying companion diagnostic. Mr. Mattes will also discuss recent milestones, including the start of Arno's Phase I clinical trial for onapristone in women with progesterone receptor positive tumors and the initiation of the Company's Phase I/II clinical trial evaluating onapristone in men with advanced castration-resistant prostate cancer.

Details of the presentation are as follows:

Investors attending the Conference who would like to schedule a 1-on-1 meeting with Arno management during the conference may do so by contacting their ROTH Capital Partners representative, or Lee Roth of The Ruth Group at [email protected].

For those unable to attend, a live webcast of Mr. Mattes' presentation will be available on the Company's website at www.arnothera.com. Following his presentation, this webcast will be archived for 90 days.

About Arno Therapeutics

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates.  These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.  For more information about the company, please visit www.arnothera.com. 

CONTACT: The Ruth Group
         Lee Roth (investors)
         [email protected]
         (646) 536-7012

         Kirsten Thomas (media)
         [email protected]
         (646) 536-7014

         Arno Therapeutics
         Glenn Mattes
         [email protected]
         (862) 703-7176

You May Also Be Interested In

• Independent Board Response to Shareholder Letter and Bluefin Bidco "No Increase" Statement
• Thousands Across America Lace Up to End Lung Cancer
• Focus Graphite Chairman Converts Final C$835,000 Loan to Equity at a Premium to Market